U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07636486) titled 'Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies' on June 04.
Brief Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept s...